Lexeo Therapeutics files $300 million shelf registration

Lexeo Therapeutics, Inc. (Nasdaq: LXEO) filed a shelf registration statement on Form S-3 with the SEC on October 29, 2026. The New York company could sell up to $300,000,000 of securities over time in one or more offerings. The shelf covers common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts and units. No offering has been priced, and no security can be sold until the SEC declares the registration effective.

What carries over from the old shelf

The filing includes $135,387,220.20 of unsold securities from an earlier Form S-3 (File No. 333-283781), filed December 13, 2024 and declared effective December 19, 2024. Under Rule 415(a)(6), the $20,727.78 filing fee paid on those unsold securities carries forward, and the earlier offering is deemed terminated when the new registration takes effect.

The S-3 names no underwriter, placement agent or sales agent, and says any used will be named in a prospectus supplement. Wilson Sonsini Goodrich & Rosati, Professional Corporation, of New York will pass on the validity of the securities.

The money behind the filing

The annual report for 2025, filed March 30, 2026, shows a net loss of $100.0 million in 2025, against a net loss of $98.3 million in 2024. Cash used in operations was $98.6 million in 2025, up from $81.2 million in 2024. Research and development expense was $63.8 million in 2025, compared with $74.1 million the year before.

Year-end 2025 cash and cash equivalents were $63.0 million, with short-term investments of $118.8 million, according to a quarterly report filed August 12, 2026. At June 30, 2026, cash and cash equivalents were $92.8 million and short-term investments were $118.9 million.

The S-3 leaves the use of any net proceeds to later prospectus supplements and says Lexeo will retain broad discretion over them.

The lead program: LX2006

Lexeo's most advanced cardiovascular candidate is LX2006, for Friedreich ataxia cardiomyopathy, in the SUNRISE-FA 2 pivotal study, which the company says is enrolling. The company plans a BLA submission in the first half of 2028 under the accelerated approval pathway, on a protocol it says incorporates FDA feedback.

The October 2025 interim update covered 17 treated participants across two studies, with efficacy data from 16 who had reached at least six months of follow-up. Among the six participants with abnormal baseline LVMI, the mean improvement was 18% at six months and 23% at 12 months. The company says the 12-month figure exceeds a 10% threshold that it describes as FDA-aligned. The mid- and high-dose cohort, three participants, showed a 33% mean improvement at 12 months. Those subgroups are small.

Across all participants, mFARS scores improved by a mean of 2.0 points from baseline at the latest visit, and eleven of sixteen reduced or stabilized. In March 2026 the company reported statistically significant improvement in mean mFARS for treated participants against a propensity-matched control cohort from the UNIFAI natural history study. That comparison is with a matched natural history group, not a randomized control.

The company says LX2006 has been generally well tolerated, with no Grade 3 treatment-related serious adverse events to date. It also reports one previously disclosed, possibly treatment-related Grade 2 event of asymptomatic myocarditis, observed one year after dosing.

The second program: LX2020

LX2020 targets arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene. It is in the Phase 1/2 HEROIC-PKP2 trial. The January 2026 interim update covered 10 participants dosed, including three at the low dose and seven at the high dose. Efficacy data came from 8 participants with at least six months of follow-up.

The company says non-sustained ventricular tachycardia was reduced or stabilized in most participants, with a 22% mean improvement in the high-dose cohorts at the latest visit, among five participants. Four of five high-dose participants reported improvement on a patient-reported scale. PKP2 protein expression rose by a mean of 93% in the low-dose cohort, with two participants, and 162% in the high-dose cohorts, with five. In August 2026 the company said the FDA granted regenerative medicine advanced therapy designation for LX2020 based on recent interim data.

These are early results from small groups, and the company presents them as interim.

Report an error

Companies in this story

LXEOLexeo Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk